Universal Ibogaine Inc. (IBO.V)

CAD 0.02

(0.0%)

Net Debt Summary of Universal Ibogaine Inc.

Universal Ibogaine Inc.'s latest annual net debt in 2022 was 1.01 Million CAD , up 277.75% from previous year.
Universal Ibogaine Inc.'s latest quarterly net debt in 2023 Q3 was 2.29 Million CAD , up 10.02% from previous quarter.
Universal Ibogaine Inc. reported annual net debt of 267.8 Thousand CAD in 2021, up 469.38% from previous year.
Universal Ibogaine Inc. reported annual net debt of -72.5 Thousand CAD in 2020, up 64.62% from previous year.
Universal Ibogaine Inc. reported quarterly net debt of 2.08 Million CAD for 2023 Q2, up 30.96% from previous quarter.
Universal Ibogaine Inc. reported quarterly net debt of 1.59 Million CAD for 2023 Q1, up 57.7% from previous quarter.

Annual Net Debt Chart of Universal Ibogaine Inc. (2022 - 2017)

Historical Annual Net Debt of Universal Ibogaine Inc. (2022 - 2017)

Year	Net Debt	Net Debt Growth
2022	1.01 Million CAD	277.75%
2021	267.8 Thousand CAD	469.38%
2020	-72.5 Thousand CAD	64.62%
2019	-204.92 Thousand CAD	-294.69%
2018	-51.92 Thousand CAD	86.61%
2017	-387.75 Thousand CAD	0.0%

Year	Net Debt	Net Debt Growth
2023 Q3	2.29 Million CAD	10.02%
2023 Q2	2.08 Million CAD	30.96%
2023 Q1	1.59 Million CAD	57.7%
2022 Q3	-94.45 Thousand CAD	0.0%
2022 Q1	-2.03 Million CAD	-29348.74%
2022 Q4	1.01 Million CAD	1170.98%
2022 FY	1.01 Million CAD	277.75%
2021 Q1	-36.88 Thousand CAD	68.86%
2021 FY	267.8 Thousand CAD	469.38%
2021 Q4	6941.00 CAD	110.97%
2021 Q3	-63.26 Thousand CAD	-904.54%
2021 Q2	7864.00 CAD	121.32%
2020 Q2	-97.66 Thousand CAD	42.03%
2020 Q1	-168.47 Thousand CAD	14.36%
2020 FY	-72.5 Thousand CAD	64.62%
2020 Q4	-118.42 Thousand CAD	-63.35%
2020 Q3	-72.5 Thousand CAD	25.77%
2019 Q3	-204.92 Thousand CAD	13.56%
2019 Q2	-237.08 Thousand CAD	6.07%
2019 Q1	-252.39 Thousand CAD	-798.76%
2019 FY	-204.92 Thousand CAD	-294.69%
2019 Q4	-196.71 Thousand CAD	4.01%
2018 Q4	-28.08 Thousand CAD	45.91%
2018 FY	-51.92 Thousand CAD	86.61%
2018 Q3	-51.92 Thousand CAD	0.0%
2018 Q1	-245.44 Thousand CAD	60.94%
2017 FY	-387.75 Thousand CAD	0.0%
2017 Q4	-628.31 Thousand CAD	0.0%

Peer Net Debt Comparison of Universal Ibogaine Inc.

Name	Net Debt	Net Debt Difference
Arch Biopartners Inc.	4.18 Million CAD	75.827%
Covalon Technologies Ltd.	-7.23 Million CAD	113.988%
Hemostemix Inc.	4.16 Million CAD	75.718%
Kane Biotech Inc.	7.52 Million CAD	86.56%
MedMira Inc.	9.25 Million CAD	89.073%
Marvel Biosciences Corp.	443.37 Thousand CAD	-128.163%
NervGen Pharma Corp.	-11.46 Million CAD	108.826%
XORTX Therapeutics Inc.	-4.53 Million CAD	122.327%